<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05020717</url>
  </required_header>
  <id_info>
    <org_study_id>20-20591</org_study_id>
    <nct_id>NCT05020717</nct_id>
  </id_info>
  <brief_title>Retrospective Survey of Hyperkalemia in Hemodialysis</brief_title>
  <acronym>Visualize-HD</acronym>
  <official_title>A Multicenter Retrospective Survey of Hyperkalemia Clinical Burden on Hemodialysis Facility-level in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aim to describe hyperkalemia clinical burden and investigate the risk factors&#xD;
      associated with the burden on HD facility level.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an observational survey study. We estimate 300 hemodialysis (HD) centres will&#xD;
      be enrolled in the study. Summarized data on serum potassium (sK) after long interdialytic&#xD;
      interval (LIDI), facility practice pattern and patient characteristics which may be related&#xD;
      with sK management, and death records information including number of deaths for each centre&#xD;
      will be collected. All the data collected and analysed are on HD facility level, not on&#xD;
      patient-level. We are aiming to describe hyperkalemia clinical burden and investigate the&#xD;
      risk factors associated with the burden on HD facility level. Association between sK&#xD;
      management and long-term outcome will also be explored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate the risk factors associated with hyperkalemia clinical burden on HD facility level</measure>
    <time_frame>3 years</time_frame>
    <description>Examine the association of risk factors at current status to hyperkalemia prevalence on HD facility level</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe hyperkalemia clinical burden on HD facility level</measure>
    <time_frame>3 years</time_frame>
    <description>Constitution ratio of different sK levels after LIDI in ranges: (0, 3.5], (3.5, 5.0], (5.0, 5.5], (5.5, 6.0], (6.0, 6.5], (6.5, 7.0], (7.0~) mmol/L in HD centers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To describe sK management pattern on HD facility level</measure>
    <time_frame>3 years</time_frame>
    <description>Proportion of patients on 3 times/week, 5 times/2 weeks, 2 times/week, less than 2 times/week, and other frequencies of HD treatment Proportion of patients with dialysate potassium concentration at 2.0 mmol/L, 2.5 mmol/L, 3.0 mmol/L and others Proportion of patients with sK testing on monthly, once per 3 months, once per &gt; 3 months and others</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate the risk factors associated with crude mortality on HD facility level</measure>
    <time_frame>3 years</time_frame>
    <description>Examine the association of risk factors back to 3 years ago to crude mortality on HD facility level, risk factors back to 3 years ago including:&#xD;
Constitution ratio of different sK levels after LIDI in ranges: (0, 3.5], (3.5, 5.0], (5.0, 5.5], (5.5, 6.0], (6.0, 6.5], (6.5, 7.0], (7.0~) mmol/L in HD centers back to 3 years ago.&#xD;
Constitution ratio of last sK levels before death in ranges: (0, 3.5], (3.5, 5.0], (5.0, 5.5], (5.5, 6.0], (6.0, 6.5], (6.5, 7.0], (7.0~) mmol/L in HD centers Key sK management factors (dialysis frequency, dialysate potassium concentration, sK testing frequency) Other factors (length of dialysis/session, patients dialysis vintage, residual renal function, etiology of ESRD, comorbidities, medication use)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To investigate the risk factors associated with sK &gt; 6.0 mmol/L and sK &gt; 6.5 mmol/L on HD facility level</measure>
    <time_frame>3 years</time_frame>
    <description>Examine the association of the facility-level risk factors at current status with sK ≥ 6.0 mmol/L and ≥ 6.5 mmol/L</description>
  </other_outcome>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Hemodialysis Complication</condition>
  <eligibility>
    <study_pop>
      <textblock>
        HD centers in China&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        For HD centers:&#xD;
&#xD;
          -  ≥ 100 patients under MHD within 3 years prior the study initiation&#xD;
&#xD;
          -  Willing to participate in the study&#xD;
&#xD;
          -  Have routine blood collection after LIDI&#xD;
&#xD;
          -  Have death records&#xD;
&#xD;
        For HD patients:&#xD;
&#xD;
        • On chronic HD for ≥ 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Blood test on other days than those after LIDI&#xD;
&#xD;
          -  Unable to provide detailed data required by study protocol&#xD;
&#xD;
          -  Being unable to comply with study-specified procedure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Zuo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Zuo</last_name>
    <phone>+86(10)88324008</phone>
    <email>zuoli@bjmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xinju Zhao</last_name>
    <phone>+86(10)88325018</phone>
    <email>zxjrmyy@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baoguo Jiang</last_name>
      <phone>+86(10)88324008</phone>
      <email>jiangbaoguo@vip.sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Li Zuo</last_name>
      <phone>+86(10)88324008</phone>
      <email>zuoli@bjmu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 17, 2021</study_first_submitted>
  <study_first_submitted_qc>August 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2021</study_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Li Zuo</investigator_full_name>
    <investigator_title>Head of the Nephrology Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

